SCHEMBL1728533

SCHEMBL1728533

CCCCc1c2c(nc3ccccc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 18/20 1.00
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
ALDH1A1 P00352 3/20 0.66
GLA P06280 3/20 0.66
KDM4E B2RXH2 2/20 0.66
TP53 P04637 2/20 0.66
HPGD P15428 2/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
STAT6 P42226 1/20 0.66
CHEK1 O14757 1/20 0.66
HDAC3 O15379 1/20 0.66
ABCC4 O15439 1/20 0.66
GMNN O75496 1/20 0.66
LMNA P02545 1/20 0.66
CYP1A2 P05177 1/20 0.66
CYP3A4 P08684 1/20 0.66
HNRNPA1 P09651 1/20 0.66
GAA P10253 1/20 0.66
ALOX15 P16050 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4455085 0.97 TOP1 (0.94) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL4557415 0.97 TOP1 (0.94) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL4453581 0.95 TOP1 (0.90) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL27588707 0.94 TOP1 (0.89) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL24513849 0.93 TOP1 (0.86) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL27606708 0.92 TOP1 (0.86) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL11070279 0.92 TOP1 (0.86) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL7976653 0.92 TOP1 (0.85) TOP1MEN1KMT2AALDH1A1GLA
SCHEMBL23432536 0.92 TOP1 (0.85) TOP1MEN1KMT2AALDH1A1GLA
Cositecan SCHEMBL15692672 0.92 TOP1 (0.85) TOP1MEN1KMT2AALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653319-B1 Formulating alkaline supersaturated aqueous solution of lipophilic derivative and solubilizer; acidifying UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2003-11-25 US claimed
US-20240156808-A1 Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases EDISON ONCOLOGY (US) 2024-05-16 US disclosed
EP-4297746-A2 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES Edison Oncology (US) 2024-01-03 EP disclosed
EP-1638978-B1 7-SUBSTITUTED CAMPTOTHECIN AND CAMPTOTHECIN ANALOGS AND METHODS FOR PREPARING SAME RES TRIANGLE INST (US) 2011-11-30 EP disclosed
EP-1883407-A4 COMPOSITIONS AND METHODS FOR TREATMENT FOR NEOPLASMS COMBINATORX INC (US) 2009-07-01 EP disclosed
EP-1638978-A4 7-SUBSTITUTED CAMPTOTHECIN AND CAMPTOTHECIN ANALOGS AND METHODS FOR PREPARING SAME RES TRIANGLE INST (US) 2008-09-17 EP disclosed
EP-1883407-A1 COMPOSITIONS AND METHODS FOR TREATMENT FOR NEOPLASMS CombinatoRx, Incorporated (US) 2008-02-06 EP disclosed
US-20060264384-A1 Compositions and methods for treatment for neoplasms COMBINATORX, INC. 2006-11-23 US disclosed
WO-2006122007-A1 COMPOSITIONS AND METHODS FOR TREATMENT FOR NEOPLASMS COMBINATORX, INCORPORATED (US) 2006-11-16 WO disclosed
US-7067666-B2 7-substituted camptothecin and camptothecin analogs and methods for producing the same RESEARCH TRIANGLE INSTITUTE (US) 2006-06-27 US disclosed
EP-1638978-A2 7-SUBSTITUTED CAMPTOTHECIN AND CAMPTOTHECIN ANALOGS AND METHODS FOR PREPARING SAME RESEARCH TRIANGLE INSTITUTE (US) 2006-03-29 EP disclosed
US-20050209263-A1 7-Substituted camptothecin and camptothecin analogs and methods for producing the same RESEARCH TRIANGLE INSITUTE (US) 2005-09-22 US disclosed
WO-2005009347-A2 7-SUBSTITUTED CAMPTOTHECIN AND CAMPTOTHECIN ANALOGS AND METHODS FOR PREPARING SAME RESEARCH TRIANGLE INSTITUTE (US) 2005-02-03 WO disclosed
US-20040266803-A1 7-Substituted camptothecin and camptothecin analogs and methods for producing the same RESEARCH TRIANGLE INSITUTE 2004-12-30 US disclosed
US-6653319-B1 Formulating alkaline supersaturated aqueous solution of lipophilic derivative and solubilizer; acidifying UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2003-11-25 US disclosed
US-RE32518-E Camptothecin derivatives KABUSHIKI KAISHA YAKULT HONSHA (JP) 1987-10-13 US disclosed
US-4399282-A 7-HYDROXYALKYL DERIVATIVES USING FREE RADICAL CATALYSTS; ANTITUMOR AND -CARCINOGENIC AGENTS; NONTOXIC KABUSHIKI KAISHA YAKULT HONSHA (JP) 1983-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266803-A1 7-Substituted camptothecin and camptothecin analogs and methods for producing the same TOP1, TOP2A, TOP2B TOP1 1/4885MEN1 1687/4885KMT2A 2828/4885
US-20240156808-A1 Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases TOP2A, TOP2B, TOP1 TOP1 3/4885MEN1 601/4885KMT2A 1727/4885
US-20060264384-A1 Compositions and methods for treatment for neoplasms MGMT, TP53, HCCS TOP1 201/4885MEN1 71/4885KMT2A 1617/4885
US-20050209263-A1 7-Substituted camptothecin and camptothecin analogs and methods for producing the same TOP1, TOP2A, TOP2B TOP1 1/4885MEN1 1687/4885KMT2A 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.